Most recently, a combination of our proposed three genetic risk markers (PNPLA3, TM6SF2, HSD17B13) into a genetic risk score was shown to be associated with an increased risk for cirrhosis and HCC in the general population [29]—further emphasizing the clinical feasibility to utilize those combined markers also, and especially, in diagnosed NAFLD patients. The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.